Savara (NASDAQ:SVRA) Earns Market Outperform Rating from JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Savara (NASDAQ:SVRA) in a report published on Thursday morning,Benzinga reports. They currently have a $9.00 target price on the stock.

SVRA has been the topic of several other reports. HC Wainwright reduced their target price on Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. Evercore ISI reiterated an “in-line” rating and set a $5.00 price target (down previously from $7.00) on shares of Savara in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, Savara presently has a consensus rating of “Moderate Buy” and an average target price of $9.86.

Savara Stock Performance

Shares of SVRA remained flat at $3.23 during trading hours on Thursday. The stock had a trading volume of 248,236 shares, compared to its average volume of 1,267,257. The company has a market cap of $554.33 million, a P/E ratio of -7.51 and a beta of 0.92. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. Savara has a 52-week low of $2.82 and a 52-week high of $5.70. The business’s 50 day moving average price is $3.48 and its two-hundred day moving average price is $3.99.

Savara (NASDAQ:SVRA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.11). Analysts forecast that Savara will post -0.45 earnings per share for the current year.

Insider Buying and Selling at Savara

In other news, CEO Matthew Pauls sold 54,702 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $3.31, for a total transaction of $181,063.62. Following the completion of the transaction, the chief executive officer now directly owns 1,536,379 shares in the company, valued at $5,085,414.49. This trade represents a 3.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Joseph S. Mccracken bought 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was bought at an average price of $2.95 per share, with a total value of $59,000.00. Following the completion of the acquisition, the director now owns 210,837 shares of the company’s stock, valued at $621,969.15. This trade represents a 10.48 % increase in their position. The disclosure for this purchase can be found here. Insiders own 5.13% of the company’s stock.

Institutional Trading of Savara

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Virtu Financial LLC acquired a new stake in Savara in the third quarter valued at $67,000. Barclays PLC increased its position in shares of Savara by 217.5% during the third quarter. Barclays PLC now owns 231,005 shares of the company’s stock worth $979,000 after purchasing an additional 158,244 shares in the last quarter. Teachers Retirement System of The State of Kentucky increased its position in shares of Savara by 148.0% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 132,425 shares of the company’s stock worth $561,000 after purchasing an additional 79,022 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Savara by 10.8% during the third quarter. Geode Capital Management LLC now owns 2,726,850 shares of the company’s stock worth $11,564,000 after purchasing an additional 264,825 shares in the last quarter. Finally, Wellington Management Group LLP increased its position in Savara by 22.9% in the 3rd quarter. Wellington Management Group LLP now owns 8,624,012 shares of the company’s stock valued at $36,566,000 after acquiring an additional 1,608,522 shares during the period. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.